MA53007A - Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives - Google Patents

Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives

Info

Publication number
MA53007A
MA53007A MA053007A MA53007A MA53007A MA 53007 A MA53007 A MA 53007A MA 053007 A MA053007 A MA 053007A MA 53007 A MA53007 A MA 53007A MA 53007 A MA53007 A MA 53007A
Authority
MA
Morocco
Prior art keywords
age
degenerative diseases
pharmaceutical association
pharmaceutical
association
Prior art date
Application number
MA053007A
Other languages
English (en)
Inventor
Ann Beliën
Original Assignee
Rejuvenate Biomed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenate Biomed filed Critical Rejuvenate Biomed
Publication of MA53007A publication Critical patent/MA53007A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
MA053007A 2018-06-29 2019-07-01 Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives MA53007A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18180906 2018-06-29

Publications (1)

Publication Number Publication Date
MA53007A true MA53007A (fr) 2021-05-05

Family

ID=62837788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053007A MA53007A (fr) 2018-06-29 2019-07-01 Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives

Country Status (15)

Country Link
US (2) US12090124B2 (fr)
EP (2) EP3813882B1 (fr)
JP (3) JP2021530459A (fr)
KR (3) KR102846956B1 (fr)
CN (1) CN112654367B (fr)
AU (2) AU2019294573B2 (fr)
BR (1) BR112020026456A2 (fr)
CA (1) CA3104397C (fr)
EA (1) EA202190151A1 (fr)
ES (1) ES2965834T3 (fr)
IL (2) IL309939A (fr)
MA (1) MA53007A (fr)
PL (1) PL3813882T3 (fr)
SG (1) SG11202012731WA (fr)
WO (1) WO2020002715A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240049717A (ko) 2022-10-07 2024-04-17 순천향대학교 산학협력단 플로리진의 노화 관련 질환의 예방 또는 치료 용도
JP2025535564A (ja) 2022-11-07 2025-10-24 リジュベネイト バイオメッド エヌブイ メトホルミンミニ錠剤
EP4615421A1 (fr) 2022-11-07 2025-09-17 Rejuvenate Biomed NV Mini-comprimés de galantamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO2000041540A2 (fr) * 1999-01-11 2000-07-20 Atanas Russinov Djananov Complement alimentaire vegetal servant a ameliorer la resistance musculaire et l'endurance d'athletes
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
NZ596244A (en) * 2006-03-29 2013-05-31 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
AU2008302190A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
WO2012012156A1 (fr) * 2010-07-21 2012-01-26 Myomics, Inc. Procédés et compositions pour l'amélioration de la fonction du muscle squelettique chez un mammifère
CN103860532B (zh) * 2014-03-11 2016-02-17 贡岳松 美金刚和二甲双胍的复方药用组合物及其制备方法
CN104623671B (zh) * 2015-02-09 2017-11-17 徐云根 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物

Also Published As

Publication number Publication date
IL279732B2 (en) 2024-06-01
AU2019294573B2 (en) 2022-03-31
ES2965834T3 (es) 2024-04-17
EP4257189A2 (fr) 2023-10-11
EP4257189A3 (fr) 2023-12-20
IL279732B1 (en) 2024-02-01
US12090124B2 (en) 2024-09-17
PL3813882T4 (pl) 2024-04-08
KR20230145380A (ko) 2023-10-17
KR20240162589A (ko) 2024-11-15
AU2022204173A1 (en) 2022-07-07
CA3104397A1 (fr) 2020-01-02
AU2019294573A1 (en) 2021-02-18
EP3813882B1 (fr) 2023-08-09
BR112020026456A2 (pt) 2021-03-23
SG11202012731WA (en) 2021-01-28
NZ772236A (en) 2024-02-23
EP3813882C0 (fr) 2023-08-09
CA3104397C (fr) 2023-08-01
IL279732A (en) 2021-03-01
WO2020002715A1 (fr) 2020-01-02
IL309939A (en) 2024-03-01
US20240390302A1 (en) 2024-11-28
US20210267918A1 (en) 2021-09-02
JP2024161512A (ja) 2024-11-19
JP2021530459A (ja) 2021-11-11
PL3813882T3 (pl) 2024-04-08
JP7542662B2 (ja) 2024-08-30
CN112654367A (zh) 2021-04-13
JP7832631B2 (ja) 2026-03-18
KR20210042312A (ko) 2021-04-19
CN112654367B (zh) 2023-08-04
EP3813882A1 (fr) 2021-05-05
KR102846956B1 (ko) 2025-08-14
JP2023055890A (ja) 2023-04-18
EA202190151A1 (ru) 2021-04-16
KR102576433B1 (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
EP4003369A4 (fr) Dérivé d'adénosine et composition pharmaceutique le comprenant
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3868409A4 (fr) Connecteur destiné à être utilisé dans un conjugué médicament anticorps et applications de connecteur
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3572050A4 (fr) Agent de traitement d'excréments destiné à être utilisé dans des colostomies
EP3345613A4 (fr) Composition pharmaceutique contenant, comme principe actif, une protéine de fusion dans laquelle un peptide pénétrant les tumeurs et un agent antiangiogenèse sont fusionnés, pour la prévention et le traitement du cancer ou de maladies associées à l'angiogenèse
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3902525A4 (fr) Compositions pharmaceutiques ophtalmiques et procédés de traitement d'une maladie de surface oculaire
EP3842423A4 (fr) Dérivé de 3-azabicyclo[3,1,1]heptane et composition pharmaceutique le comprenant
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EP3643723C0 (fr) Nouveau peptide et composition pharmaceutique pour le traitement de maladies oculaires comprenant ledit nouveau peptide en tant que principe actif
EP3523281A4 (fr) Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
EP3645120A4 (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
EP4329753A4 (fr) Compositions pharmaceutiques et systèmes d'administration intravitréenne de médicament pour le traitement de maladies oculaires
EP4259188A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états pathologiques apparentés
EP3472133A4 (fr) Inhibiteurs de perk et utilisations associées dans le traitement de maladies associées à des protéines sujettes à l'agrégation
EP3877028A4 (fr) Appareil d'assistance respiratoire et/ou composants associés
EP3766503A4 (fr) Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires
IL279732A (en) Medicinal combination for use in age-related and/or degenerative diseases
EP3452051A4 (fr) Composition comprenant du hmos destinée à être utilisée dans le traitement de l'hypersensibilité et/ou de la douleur viscérale médiée par les mastocytes
EP3752088A4 (fr) Plateforme et système destinés à être utilisés dans des procédures thérapeutiques